FOLH1 and neoplasm: In addition, other reports have shown the expression of GRPr in metastatic lymph nodes, bones, and advanced tumor stages [11,52], suggesting the clinical potential of GRPr as a target for PET imaging and RLT and as an alternative to PSMA.